Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

A cancer-causing protein long thought to be resistant to medication could soon be the target of new drugs, thanks to the work ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Decades of research have shown that mutant RAS proteins promote the development and growth of tumors by activating specific proteins at the cell surface, creating a constant stream of signals ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on ...

The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043SAN DIEGO, April 23, 2025 ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating rat sarcoma (RAS)-driven cancers. This trial aims to assess VVD-159642’s ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Duyk said the $30 million in funding has helped Grove Biopharma expand from "about four people working on this" to a current 10-person headcount and allowed it to move from Portal Innovations' labs to ...